<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stress testing: The effect of medications and methylxanthines</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stress testing: The effect of medications and methylxanthines</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stress testing: The effect of medications and methylxanthines</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Panithaya Chareonthaitawee, MD, FACC, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J. Wells Askew, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary V Heller, MD, PhD, FACC, MASNC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6560911"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For the majority of patients undergoing a stress test, the primary goal is to identify myocardial ischemia due to coronary heart disease (CHD). Depending on the stress test modality, ischemia may manifest in the form of symptoms, hemodynamic findings, electrocardiographic abnormalities, stress-induced perfusion defects, or regional wall motion abnormalities. </p><p>In patients with known or suspected CHD, the presence and extent of ischemia on stress testing are used to guide medical therapy and/or determine the need for further diagnostic and therapeutic procedures. Thus, factors that impact the sensitivity and specificity of stress testing for the detection of ischemia may lead to either patients not receiving appropriate therapy or to unnecessary procedures and treatment with their attendant risks and costs, respectively. Many factors (eg, pre-existing electrocardiographic abnormalities, sex, body habitus, etc) can affect a stress test’s ability to accurately identify myocardial ischemia.</p><p>The interaction between major cardiovascular medications, dietary factors (namely items containing caffeine), and stress testing and our recommendations for continuing or discontinuing the individual drug or dietary component will be discussed here. Indications and procedures for stress testing are discussed separately. (See  <a class="medical medical_review" href="/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a> and  <a class="medical medical_review" href="/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a> and  <a class="medical medical_review" href="/d/html/5328.html" rel="external">"Overview of stress radionuclide myocardial perfusion imaging"</a> and  <a class="medical medical_review" href="/d/html/5310.html" rel="external">"Overview of stress echocardiography"</a>.)</p><p class="headingAnchor" id="H1292639725"><span class="h1">STRESS TESTING CONCEPTS</span><span class="headingEndMark"> — </span>Before discussing the impact of medications and dietary factors on the detection of myocardial ischemia on stress testing, important concepts regarding stress testing for coronary heart disease (CHD) must be considered. </p><p class="bulletIndent1"><span class="glyph">●</span>The manifestations of CHD identified following stress with exercise or <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> require the ability to increase myocardial oxygen demand by increasing heart rate, blood pressure, and/or left ventricular contractility above a certain threshold to provoke myocardial ischemia. Vasodilator-stress induced manifestations of CHD depend on a hyperemic coronary blood flow differential between normal and abnormal coronary arteries, and are not dependent on increasing heart rate, blood pressure, or contractility. (See  <a class="medical medical_review" href="/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a> and  <a class="medical medical_review" href="/d/html/5328.html" rel="external">"Overview of stress radionuclide myocardial perfusion imaging"</a> and  <a class="medical medical_review" href="/d/html/5310.html" rel="external">"Overview of stress echocardiography"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While the presence of myocardial ischemia on stress testing generally correlates with the extent and severity of angiographic epicardial coronary artery stenosis, in a subset of patients, microvascular dysfunction and/or lesions not visible by standard invasive coronary angiography may produce myocardial ischemia on stress testing. Thus, a positive stress test in the absence of angiographic stenosis is not always a false positive test given the limitations of conventional coronary angiography. (See  <a class="medical medical_review" href="/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the goals of medical and procedural therapies to treat CHD is to alleviate symptoms by reducing myocardial ischemia. As such, the goal of stress testing in patients with established (and treated) CHD is to consider the effectiveness of therapy, and this goal should be taken into consideration when deciding whether to continue or discontinue medications for stress testing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many factors influence a stress test’s ability to identify myocardial ischemia. For the exercise electrocardiogram, common factors that affect the sensitivity and/or specificity include pre-existing electrocardiographic abnormalities, workload, sex, and prior coronary revascularization. For most imaging modalities, large body habitus may be associated with artifacts and limitations that can reduce both the sensitivity and the specificity of the test. Thus, although certain medications and dietary elements may affect the performance of both exercise and pharmacologic stress testing, a comprehensive understanding of the limitations of invasive coronary angiography in identifying CHD as well as a review of other factors that may affect test performance are crucial to clinical decision making. (See  <a class="medical medical_review" href="/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a> and  <a class="medical medical_review" href="/d/html/5328.html" rel="external">"Overview of stress radionuclide myocardial perfusion imaging"</a> and  <a class="medical medical_review" href="/d/html/5310.html" rel="external">"Overview of stress echocardiography"</a>.)</p><p></p><p class="headingAnchor" id="H947661990"><span class="h1">OUR APPROACH TO MEDICATIONS AND STRESS TESTING</span><span class="headingEndMark"> — </span>In general, our approach, which is consistent with professional society guidelines, is to continue all or nearly all medications at the time of stress testing. Rarely, if the stress test is being performed primarily to diagnose the presence and/or extent of coronary heart disease (CHD), we will withhold certain medication(s) prior to stress testing (eg, methylxanthines, beta blockers, calcium channel blockers) in order to optimize the sensitivity and specificity of the test, but only after weighing the risks and benefits of withholding the medication(s) and considering possible alternatives.</p><p>The decision to continue or discontinue any medication(s) or to make certain dietary modifications prior to stress testing should be made on an individual basis. Factors involved in this decision include the indication for stress testing, indication for any medication(s) the patient is taking which may need to be stopped, and the potential harm to the patient from temporarily discontinuing the medication(s).</p><p>To obtain the maximal benefit of stopping any medication(s), the medication(s) should be withheld for four to five half-lives <strong>prior to</strong> the stress test being performed. Discontinuation of therapies for four to five half-lives will reverse the hemodynamic impact of antianginal treatment with nitrates, beta blockers, and calcium channel blockers. This can be accomplished, when practical and safe for the patient, by withholding antianginal medications such as beta blockers, calcium channel blockers, and nitrates for at least 48 hours prior to a diagnostic stress test [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H3068048437"><span class="h1">MEDICATIONS THAT MAY REDUCE TEST SENSITIVITY</span><span class="headingEndMark"> — </span>There are a number of medications and substances (eg, beta blockers, calcium channel blockers, caffeine, etc) that may alter the sensitivity of stress testing. In general, these medications impact heart rate, blood pressure, or both, with the notable exception of methylxanthines, which impact vasodilator stress testing via their effect on <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> 2A receptors. </p><p class="headingAnchor" id="H2443647216"><span class="h2">Methylxanthines</span><span class="headingEndMark"> — </span>Methylated xanthines (ie, methylxanthines) should be withheld prior to stress testing with vasodilator agents. In our practice, we withhold caffeine-containing products (a list of which can be accessed <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcspinet.org%2Feating-healthy%2Fingredients-of-concern%2Fcaffeine-chart&amp;token=BEvxzPGUIMUKdBvnGquDJADAFpC2ZOBpUsaiXSsZe%2ByBos55zMyhICWSNt6lbUYIXiBRT9G6YM7K%2BQY7QnWGR%2BPcHGBSbhEJzFm5nz0AIIs%3D&amp;TOPIC_ID=5305" target="_blank">here</a>) and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> for at least 12 hours before the test and dipyridamole-containing medications for at least 48 hours, a practice that is consistent with professional society guidelines [<a href="#rid1">1</a>]. </p><p>If caffeine has been consumed within 12 hours of the start of the vasodilator infusion, options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise instead of vasodilator as the stress mechanism, if feasible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">Dobutamine</a> instead of vasodilator stress as the stress mechanism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A two-day rest-stress SPECT MPI protocol with resting imaging on day 1 and vasodilator stress testing and imaging on day 2 with no caffeine for at least 12 hours prior to the vasodilator stress administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rescheduling on a different day and reinforcing the importance of not consuming caffeine for at least 12 hours prior to the test.</p><p></p><p>In patients with recent (&lt;48 hours) use of oral <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> or medications containing dipyridamole (eg, Aggrenox), <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> and <a class="drug drug_general" data-topicid="9462" href="/d/drug information/9462.html" rel="external">regadenoson</a> are contraindicated; however, exercise testing, or pharmacologic stress testing utilizing IV dipyridamole or <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> may be administered safely and efficaciously [<a href="#rid1">1</a>].</p><p>Methylxanthines, including caffeine, <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a>, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a>, and theobromine, are competitive inhibitors of <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> receptors and may significantly attenuate the coronary vasodilatory effects of all vasodilator stress agents used for stress imaging through its effects on A2A receptors, which mediate coronary vasodilation. In a multicenter, double-blind, randomized study to investigate the effects of caffeine on radionuclide myocardial perfusion imaging (rMPI) in patients with coronary heart disease (CHD), individuals with at least one segment with a reversible defect received caffeine tablets (200 or 400 mg) or placebo 90 minutes before a repeat <a class="drug drug_general" data-topicid="9462" href="/d/drug information/9462.html" rel="external">regadenoson</a> stress SPECT five days after the initial study [<a href="#rid2">2</a>]. The mean number of segments with reversible defects decreased in both groups who received caffeine, compared with no significant change in the placebo group. </p><p>These findings are generally in agreement with nonrandomized smaller human studies and animal experiments. However, two studies (one using positron emission tomography [PET], one using SPECT) have reported discordant findings to those described in the randomized trial of caffeine [<a href="#rid3">3,4</a>]. Both studies were small (fewer than 50 patients), and the average dose of caffeine was 200 mg in one study [<a href="#rid4">4</a>] and significantly lower in the other study [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2166815195"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>In our practice, we do not routinely discontinue beta blocker therapy prior to stress testing. If the stress test is being performed primarily to diagnose the presence and/or extent of CHD, we will rarely withhold beta blocker therapy prior to stress testing in order to optimize the sensitivity and specificity of the test, but only after weighing the risks and benefits of withholding the medication and considering possible alternatives. This is done on a case-by-case basis. Other practices may routinely withhold beta blocker therapy prior to testing in order to enhance test sensitivity [<a href="#rid5">5</a>].</p><p>The effects of beta blockers on the performance of both exercise testing and pharmacologic stress imaging have been inconsistent, with insufficient data to recommend withholding beta blocker therapy in all patients referred for stress testing. This is in line with 2002 American College of Cardiology/American Heart Association (ACC/AHA) Exercise Testing Guidelines and the 2016 American Society of Nuclear Cardiology (ASNC) imaging guidelines for SPECT nuclear cardiology procedures, which state that the discontinuation of these medications is left to the discretion of the referring provider and that it appears unnecessary for physicians to accept the risk of stopping beta blockers before testing when a patient exhibits possible symptoms of ischemia [<a href="#rid1">1,6</a>]. </p><p>Beta blockers decrease myocardial oxygen demand by reducing myocardial contractility, heart rate, and blood pressure. </p><p class="bulletIndent1"><span class="glyph">●</span>Nonselective beta blockers share some of the same pathways as the <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> 2A receptors through their interaction with beta-2 receptors and may interfere with adenosine induced vasodilation [<a href="#rid7">7-11</a>]. This is probably the same mechanism which interferes with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> induced vasodilation [<a href="#rid12">12-14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonselective beta blockers will also prevent the paradoxical vasoconstriction in abnormal coronary arteries [<a href="#rid7">7,15,16</a>]. The resulting favorable effect on vasomotor tone may have the added benefit of preventing coronary steal and improving endocardial perfusion [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversely, selective beta blockers without vasodilating properties may cause vasoconstriction and decreased flow in normal coronaries.</p><p></p><p>Despite these mechanistic properties of beta blockers and decades of exercise and pharmacologic stress testing, there are conflicting data and no large-scale studies on the effect of beta blocker use on the performance of stress testing. No consensus exists on withholding or continuing beta-blocker treatment before either exercise or pharmacologic stress testing. </p><p class="bulletIndent1"><span class="glyph">●</span>Although beta blockers have been shown to markedly reduce maximal exercise heart rate, no differences in exercise stress test performance were found in a cohort of 3047 men being evaluated for possible CHD (including 2847 taking beta blockers and 200 not taking beta blockers) [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For exercise rMPI, small nonrandomized clinical studies suggest an overall decrease in the sensitivity in detecting coronary artery disease (CAD) in patients on beta blockers [<a href="#rid19">19,20</a>]. In one of these studies, patients with chronic stable angina and CHD undergoing exercise <a class="drug drug_general" data-topicid="101540" href="/d/drug information/101540.html" rel="external">thallium-201</a> SPECT demonstrated significantly smaller perfusion defects both with exercise and with redistribution in the group receiving beta blockers compared with placebo even though beta blockers were held 48 hours before the stress test [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small retrospective cohort studies have evaluated the effects of beta-blocker use on vasodilator stress rMPI with mixed results, with studies showing both reduced sensitivity and no reduction in sensitivity for detection of CHD with versus without beta blockers [<a href="#rid11">11,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies have also shown decreased sensitivity of stress echocardiography for the detection of ischemia in patients treated with beta blockers. The anti-ischemic effects of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> were demonstrated in a study of 17 patients with known reversible defects on rMPI who subsequently underwent simultaneous <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography and technetium-99m sestamibi MPI both before and after propranolol administration; heart rate, rate-pressure product, extent and severity of perfusion defects, and the number of abnormal echocardiographic segments were smaller after propranolol administration [<a href="#rid22">22</a>].</p><p></p><p>In patients who fail to achieve 85 percent of their maximal predicted heart rate during <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress testing, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> has been used to augment the heart rate response. Administration of atropine improves the hemodynamic response to dobutamine in the setting of beta-blocker administration, decreases the number of inconclusive tests [<a href="#rid23">23</a>], and increases the recognition of ischemia [<a href="#rid24">24</a>]. However, the effect of beta blockers to reduce the severity of dobutamine-induced echocardiographic segmental wall motion abnormalities is not completely abolished with atropine administration [<a href="#rid25">25</a>]. Again, however, studies are limited in number, sample size, and study design.</p><p class="headingAnchor" id="H3835635188"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>In our practice, we do not routinely discontinue calcium channel blocker therapy prior to stress testing. Rarely, if the stress test is being performed primarily to diagnose the presence and/or extent of CHD, we will withhold calcium channel blocker therapy prior to stress testing in order to optimize the sensitivity and specificity of the test, but only after weighing the risks and benefits of withholding the medications and considering possible alternatives. This is done on a case-by-case basis.</p><p>Similar to beta blockers, studies examining the effects of calcium channel blockers on stress testing performance have been small and nonrandomized. However, given the small number of studies, there is insufficient evidence to recommend withholding calcium channel blocker therapy in all patients referred for stress testing. This is in line with the 2016 ASNC imaging guidelines for SPECT nuclear cardiology procedures, which state that the discontinuation of these medications is left to the discretion of the referring provider [<a href="#rid1">1</a>]. For example, if the patient has known CHD on medical therapy and requires a stress test for follow-up assessment, we would perform the stress test while the patient remains on the calcium channel blocker to test the effectiveness of medical therapy. On the other hand, if a patient on a calcium channel blocker for hypertension is referred for new symptoms suggesting angina in the absence of known CHD, the provider may stop the calcium channel blocker prior to stress testing if it is deemed safe to do so.</p><p>Calcium channel blockers have effective antianginal properties that are comparable to beta blockers [<a href="#rid26">26</a>]. However, they are different in their effect on the myocardium (contractility, heart rate) and peripheral vasculature. Calcium channel blockers increase coronary blood flow and reduce myocardial oxygen demand, which results in improved diastolic and systolic function [<a href="#rid27">27,28</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Three studies of patients with chronic stable angina receiving <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> showed improvements in exercise duration and ST segment changes during exercise stress testing compared with those who received placebo [<a href="#rid29">29-31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of patients who underwent dobutamine-atropine stress echocardiography who had angiographically documented CHD, antianginal treatment with calcium channel blockers (<a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) decreased the sensitivity of the test for detection of ischemia from 100 to 88 percent, increased the requirement for <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> administration, and reduced the severity of echocardiographic findings [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who underwent <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> <a class="drug drug_general" data-topicid="101540" href="/d/drug information/101540.html" rel="external">thallium-201</a> MPI with and without anti-ischemic treatment (serving as their own controls), treatment with antianginal drugs (calcium channel blockers in 81 percent) resulted in reduced size and severity of MPI defects [<a href="#rid33">33</a>]. This study also demonstrated a reduction in sensitivity for the detection of single vessel CHD with the use of calcium channel blockers.</p><p></p><p class="headingAnchor" id="H881127296"><span class="h2">Nitrates</span><span class="headingEndMark"> — </span>Similar to other vasoactive medications, studies examining the effects of nitrates on stress testing performance have been small and nonrandomized. Furthermore, long-acting nitrates are generally not utilized in patients without presumed or known CHD. There is insufficient evidence to recommend withholding nitrate therapy in patients referred for stress testing, especially since testing in situations following nitrate treatment may be to assess the effectiveness of medical therapy. This is in line with the 2016 ASNC imaging guidelines for SPECT nuclear cardiology procedures, which state that the discontinuation of these medications is left to the discretion of the referring provider [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Nitrates have been shown to dilate large epicardial vessels and smaller resistance vessels and also decrease diastolic filling pressure, thereby increasing coronary perfusion, decreasing coronary steal, and improving myocardial perfusion [<a href="#rid34">34-37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nitrates may also prevent exercise-induced paradoxical coronary vasoconstriction [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with known CHD undergoing exercise stress testing have been shown to have a delay in the onset and reduced magnitude of ST-segment depression with long-acting nitrate administration [<a href="#rid39">39</a>]. </p><p></p><p>Nitrate therapy has been shown to reduce the extent and severity of ischemia assessed by exercise MPI despite having no significant effect on heart rate, blood pressure, or double product (product of heart rate and systolic blood pressure) [<a href="#rid40">40,41</a>]. Similar results have been observed in patients receiving nitrate therapy who have undergone <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography and <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> stress <a class="drug drug_general" data-topicid="101540" href="/d/drug information/101540.html" rel="external">thallium-201</a> MPI [<a href="#rid32">32,33</a>]. </p><p class="headingAnchor" id="H2279127144"><span class="h2">Angiotensin converting enzyme inhibitors and angiotensin receptor blockers</span><span class="headingEndMark"> — </span>In our practice, we do not discontinue therapy with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) prior to stress testing.</p><p>In animal experiments, ACEI have been shown to increase coronary blood flow at rest and during myocardial ischemia as well as to reduce experimental infarct size [<a href="#rid42">42-44</a>]. These beneficial effects are assumed to be secondary to nitric oxide-dependent vasodilation and accumulation of bradykinin. In human studies, ACEI have demonstrated several beneficial hemodynamic effects, including attenuation of acetylcholine-induced coronary vasoconstriction [<a href="#rid45">45</a>] improvement in endothelium-dependent brachial artery flow-mediated vasodilation [<a href="#rid46">46</a>], attenuation of sympathetic coronary vasoconstriction [<a href="#rid47">47</a>], and optimization of myocardial metabolism [<a href="#rid48">48</a>].</p><p>One study in humans measuring myocardial blood flow (using PET) in symptomatic patients with CHD demonstrated that the acute administration of quinaprilat 10 mg IV increased myocardial blood flow to ischemic regions [<a href="#rid49">49</a>]. However, other studies of patients with known myocardial ischemia and CHD treated with ACEI have shown no reduction in ischemia at one and three weeks but did demonstrate increased time to ST segment depression (ie, ischemia) only after 12 weeks of treatment [<a href="#rid50">50,51</a>]. </p><p>ARBs may improve endothelial function, as shown by reports of their favorable effect on brachial artery flow-mediated vasodilation and improvement in coronary microvascular function and flow reserve [<a href="#rid52">52,53</a>]. One study of myocardial blood flow (using PET and <a class="drug drug_general" data-topicid="93421" href="/d/drug information/93421.html" rel="external">N-13 ammonia</a>) in 16 patients with mild stable coronary heart disease revealed improved endothelial-dependent flow increase and adenosine-induced vasodilation following <a class="drug drug_general" data-topicid="10036" href="/d/drug information/10036.html" rel="external">valsartan</a> administration [<a href="#rid54">54</a>]. Notably, the improvement in coronary flow preceded any reduction in blood pressure. </p><p class="headingAnchor" id="H1426450004"><span class="h2">L-arginine</span><span class="headingEndMark"> — </span>In our practice, we do not routinely discontinue L-arginine therapy prior to stress testing, given the limited data.</p><p>L-arginine administration improves brachial artery flow-mediated dilation and augments coronary endothelium-dependent vasodilation in patients with microvascular angina [<a href="#rid55">55,56</a>]. In a double-blind, placebo-controlled study of 22 patients with stable angina, oral supplementation of 6 g/day of L-arginine increased exercise duration, maximum workload, and time to onset of ST-segment depression [<a href="#rid57">57</a>]. </p><p class="headingAnchor" id="H2485888848"><span class="h1">MEDICATIONS THAT MAY REDUCE THE SPECIFICITY OF THE STRESS TEST</span><span class="headingEndMark"> — </span>There are fewer medications and substances that may reduce the specificity of the test compared with those that may reduce the sensitivity of the test. In general, these medications alter the response of the electrocardiogram (ECG), producing changes suggestive of ischemia when no ischemia is present.</p><p class="headingAnchor" id="H2642522839"><span class="h2">Digoxin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> is probably the most widely known medication that can produce ECG changes at rest and during exercise stress testing in the absence of angiographic coronary heart disease (CHD). In our practice, we do not routinely discontinue digoxin therapy prior to stress testing. This is in agreement with the 2002 American College of Cardiology/American Heart Association (ACC/AHA) exercise testing guidelines which recommend beginning with an exercise ECG stress test in patients taking digoxin with less than 1 mm of ST depression. However, in patients taking digoxin with greater than 1 mm resting ST depression, or those in whom an exercise test without imaging was nondiagnostic or indeterminate, an exercise test with imaging may be performed [<a href="#rid6">6</a>]. </p><p><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> can induce coronary vasoconstriction leading to decreased subendocardial perfusion and may also increase intracellular calcium concentrations [<a href="#rid34">34,58</a>]. However, the effect on ST depression may not be due to this vasoconstriction since the administration of nitrates has been shown to reverse the vasoconstriction but not the ECG changes [<a href="#rid58">58</a>]. The effect of digoxin on Na/K ATPase may change the cellular membrane depolarization, and this could also result in ECG changes in the absence of ischemia.</p><p>In two studies, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> produced abnormal exercise-induced ST depression in 25 to 40 percent of apparently healthy normal subjects, and the effect is directly related to age [<a href="#rid59">59,60</a>]. This effect was not present after the discontinuation of digoxin for 12 days, but the latter is not a practical approach in the clinical setting [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H158201805"><span class="h2">Estrogens</span><span class="headingEndMark"> — </span>In our practice, we do not routinely discontinue estrogen therapy prior to stress testing.</p><p>In general, there is a paucity of conclusive data regarding the effects of estrogen on stress testing. </p><p class="bulletIndent1"><span class="glyph">●</span>In premenopausal women, the accuracy of the exercise ECG has been shown to vary with estrogen levels during the menstrual cycle [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study demonstrated more ST segment depression in 90 percent of patients with established CHD after two weeks of treatment with estrogens [<a href="#rid62">62</a>]. In another study, normalization of an abnormal ST segment response to exercise was seen in women undergoing repeat exercise testing following an intervening oophorectomy [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of 404 women with normal radionuclide myocardial perfusion imaging (rMPI) following exercise stress testing reported a significantly higher rate of ECG positivity in women taking hormone replacement therapy [<a href="#rid64">64</a>]. </p><p></p><p>These studies, however, have many limitations, and no current recommendations exist to withhold estrogen therapy prior to stress testing or to use specific types of tests.</p><p class="headingAnchor" id="H251942176"><span class="h2">Diuretics</span><span class="headingEndMark"> — </span>Stress testing should not be performed in patients with profound hypokalemia. For potassium levels between 3 and 4 mEq/L, stress testing may be considered on a case-by-case basis [<a href="#rid65">65,66</a>]. </p><p>Diuretics can be associated with ECG changes due to electrolyte imbalances. In patients with significant hypokalemia (below 3 mEq/L), exercise testing should be delayed until adequate potassium repletion has occurred. The ECG changes are less prominent at potassium levels between 3 and 4 mEq/L, and patients may begin with exercise testing without imaging, but others may also begin with stress imaging, especially if more prominent ECG changes are present.</p><p class="headingAnchor" id="H2103601514"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122212.html" rel="external">"Society guideline links: Stress testing and cardiopulmonary exercise testing"</a>.)</p><p class="headingAnchor" id="H2611606636"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Medications and dietary ingestions may reduce the ability of an exercise electrocardiogram (ECG) or stress imaging test to detect myocardial ischemia and coronary heart disease (CHD). The decision to continue or withhold any medications or dietary ingestions prior to stress testing must be individualized according to the specific medication or the dietary ingestion, and the patient-specific factors. (See <a class="local">'Introduction'</a> above and <a class="local">'Stress testing concepts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, our approach, which is consistent with professional society guidelines, is to continue all or nearly all medications at the time of stress testing. Rarely, if the stress test is being performed primarily to diagnose the presence and/or extent of CHD, we will withhold certain medication(s) prior to stress testing, but only after weighing the risks and benefits of withholding the medication(s) and considering possible alternatives. (See <a class="local">'Our approach to medications and stress testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We ask patients to withhold caffeine at least 12 hours and dipyridamole-containing medications for at least 48 hours prior to vasodilator stress testing. If caffeine has been consumed, then options include (see <a class="local">'Methylxanthines'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exercise stress testing instead of vasodilator stress testing (if feasible)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">Dobutamine</a> stress testing instead of vasodilator stress testing</p><p class="bulletIndent3"><span class="glyph">-</span>A two-day rest-stress SPECT MPI protocol with resting imaging on day 1 and stress testing and imaging on day 2 following at least 12 hours without caffeine</p><p class="bulletIndent3"><span class="glyph">-</span>Having the patient return on a different day and reinforce the importance of not consuming caffeine for at least 12 hours prior to the test</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta blockers, calcium channel blockers, and nitrates – We <strong>do not</strong> routinely discontinue therapy with beta blockers, calcium channel blockers, and nitrates <strong>in all patients</strong> referred for stress testing. This approach is based on limited data showing inconsistent results from withholding therapy. However, <strong>in select patients</strong> in whom the stress test is being performed primarily to diagnose the presence and/or extent of CHD, we will rarely withhold therapy prior to stress testing in order to optimize the sensitivity and specificity of the test, but only after weighing the risks and benefits of withholding the medications and considering possible alternatives. This is done on a case-by-case basis. </p><p></p><p class="bulletIndent2">If testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment with beta blockers, calcium channel blockers, and nitrates should be continued. (See <a class="local">'Beta blockers'</a> above and <a class="local">'Calcium channel blockers'</a> above and <a class="local">'Nitrates'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) – We <strong>do not</strong> discontinue therapy with an ACEI or ARB prior to stress testing, based on limited available data which are inconclusive regarding the effect of ACEIs or ARBs on the results. (See <a class="local">'Angiotensin converting enzyme inhibitors and angiotensin receptor blockers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> – While digoxin can cause ECG changes during exercise stress testing in the absence of angiographic CHD, we <strong>do not</strong> routinely discontinue digoxin therapy prior to stress testing. In patients taking digoxin with greater than 1 mm resting ST depression, or those in whom an exercise test without imaging was nondiagnostic or indeterminate, an exercise test with imaging should be performed. (See <a class="local">'Digoxin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diuretics – Stress testing should not be performed in patients with profound hypokalemia. In our practice, we do not routinely discontinue diuretics prior to stress testing. (See <a class="local">'Diuretics'</a> above.)</p><p></p><p class="headingAnchor" id="H462911210"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The authors and UpToDate thank Dr. Sarkis Baghdasarian, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 2016; 23:606.</a></li><li><a class="nounderline abstract_t">Tejani FH, Thompson RC, Kristy R, Bukofzer S. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. Int J Cardiovasc Imaging 2014; 30:979.</a></li><li><a class="nounderline abstract_t">Zoghbi GJ, Htay T, Aqel R, et al. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 2006; 47:2296.</a></li><li><a class="nounderline abstract_t">Gaemperli O, Schepis T, Koepfli P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008; 51:328.</a></li><li><a class="nounderline abstract_t">Zoghbi GJ, Dorfman TA, Iskandrian AE. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008; 52:401.</a></li><li><a class="nounderline abstract_t">Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531.</a></li><li><a class="nounderline abstract_t">Bortone AS, Hess OM, Gaglione A, et al. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990; 81:1225.</a></li><li><a class="nounderline abstract_t">Kern MJ, Ganz P, Horowitz JD, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation 1983; 67:1178.</a></li><li><a class="nounderline abstract_t">Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade. Circ Res 1983; 53:389.</a></li><li><a class="nounderline abstract_t">Picano E. Dipyridamole-echocardiography test: historical background and physiologic basis. Eur Heart J 1989; 10:365.</a></li><li><a class="nounderline abstract_t">Taillefer R, Ahlberg AW, Masood Y, et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003; 42:1475.</a></li><li><a class="nounderline abstract_t">Vatner SF, Hintze TH, Macho P. Regulation of large coronary arteries by beta-adrenergic mechanisms in the conscious dog. Circ Res 1982; 51:56.</a></li><li><a class="nounderline abstract_t">Hodgson JM, Cohen MD, Szentpetery S, Thames MD. Effects of regional alpha- and beta-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans. Circulation 1989; 79:797.</a></li><li><a class="nounderline abstract_t">Ferro A, Kaumann AJ, Brown MJ. Beta-adrenoceptor subtypes in human coronary artery: desensitization of beta 2-adrenergic vasorelaxation by chronic beta 1-adrenergic stimulation in vitro. J Cardiovasc Pharmacol 1995; 25:134.</a></li><li><a class="nounderline abstract_t">RIVER GL, ROBBINS AB, SCHWARTZ SO. S-C hemoglobin: a clinical study. Blood 1961; 18:385.</a></li><li><a class="nounderline abstract_t">Chierchia S, Muiesan L, Davies A, et al. Role of the sympathetic nervous system in the pathogenesis of chronic stable angina. Implications for the mechanism of action of beta-blockers. Circulation 1990; 82:II71.</a></li><li><a class="nounderline abstract_t">Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993; 71:177.</a></li><li><a class="nounderline abstract_t">Herbert WG, Dubach P, Lehmann KG, Froelicher VF. Effect of beta-blockade on the interpretation of the exercise ECG: ST level versus delta ST/HR index. Am Heart J 1991; 122:993.</a></li><li><a class="nounderline abstract_t">Narahara KA, Thompson CJ, Hazen JF, et al. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 1989; 117:1030.</a></li><li><a class="nounderline abstract_t">Martin GJ, Henkin RE, Scanlon PJ. Beta blockers and the sensitivity of the thallium treadmill test. Chest 1987; 92:486.</a></li><li><a class="nounderline abstract_t">Fallahi B, Beiki D, Akbarpour S, et al. Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial. Daru 2013; 21:8.</a></li><li><a class="nounderline abstract_t">Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 1997; 80:268.</a></li><li><a class="nounderline abstract_t">Camarozano AC, Siqueira-Filho AG, Weitzel LH, et al. The effects of early administration of atropine during dobutamine stress echocardiography: advantages and disadvantages of early dobutamine-atropine protocol. Cardiovasc Ultrasound 2006; 4:17.</a></li><li><a class="nounderline abstract_t">Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28:551.</a></li><li><a class="nounderline abstract_t">Chen L, Ma L, de Prada VA, et al. Effects of beta-blockade and atropine on ischemic responses in left ventricular regions subtending coronary stenosis during dobutamine stress echocardiography. J Am Coll Cardiol 1996; 28:1866.</a></li><li><a class="nounderline abstract_t">Follath F. The role of calcium antagonists in the treatment of myocardial ischemia. Am Heart J 1989; 118:1093.</a></li><li><a class="nounderline abstract_t">Pepine CJ, Lambert CR. Effects of nicardipine on coronary blood flow. Am Heart J 1988; 116:248.</a></li><li><a class="nounderline abstract_t">Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29:387.</a></li><li><a class="nounderline abstract_t">Moskowitz RM, Piccini PA, Nacarelli GV, Zelis R. Nifedipine therapy for stable angina pectoris: preliminary results of effects on angina frequency and treadmill exercise response. Am J Cardiol 1979; 44:811.</a></li><li><a class="nounderline abstract_t">Fox KM, Deanfield J, Jonathan A, Selwyn A. The dose-response effects of nifedipine of ST-segment changes in exercise testing: preliminary studies. Cardiology 1981; 68 Suppl 2:209.</a></li><li><a class="nounderline abstract_t">Rice KR, Gervino E, Jarisch WR, Stone PH. Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina pectoris. Am J Cardiol 1990; 65:1097.</a></li><li><a class="nounderline abstract_t">Dodi C, Pingitore A, Sicari R, et al. Effects of antianginal therapy with a calcium antagonist and nitrates on dobutamine-atropine stress echocardiography. Comparison with exercise electrocardiography. Eur Heart J 1997; 18:242.</a></li><li><a class="nounderline abstract_t">Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. J Am Coll Cardiol 1998; 31:1540.</a></li><li class="breakAll">Ellestad M. Stress Testing Principles and Practice, Oxford University Press, Inc, New York 2003.</li><li><a class="nounderline abstract_t">Hintze TH, Vatner SF. Comparison of effects of nifedipine and nitroglycerin on large and small coronary arteries and cardiac function in conscious dogs. Circ Res 1983; 52:I139.</a></li><li><a class="nounderline abstract_t">Nagao T, Murata S, Sato M. Effects of diltiazem (CRD-401) on developed coronary collaterals in the dog. Jpn J Pharmacol 1975; 25:281.</a></li><li><a class="nounderline abstract_t">Fallen EL, Nahmias C, Scheffel A, et al. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. Circulation 1995; 91:1381.</a></li><li><a class="nounderline abstract_t">Bortone AS, Hess OM, Eberli FR, et al. Abnormal coronary vasomotion during exercise in patients with normal coronary arteries and reduced coronary flow reserve. Circulation 1989; 79:516.</a></li><li><a class="nounderline abstract_t">Wayne VS, Fagan ET, McConachy DL. The Effects of Isosorbide Dinitrate on the Exercise Test. J Cardiopulm Rehabil Prev 1987; 7:239.</a></li><li><a class="nounderline abstract_t">Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 1994; 24:25.</a></li><li><a class="nounderline abstract_t">Tono I, Satoh S, Kanaya T, et al. Alterations in myocardial perfusion during exercise after isosorbide dinitrate infusion in patients with coronary disease: assessment by thallium-201 scintigraphy. Am Heart J 1986; 111:525.</a></li><li><a class="nounderline abstract_t">Sudhir K, Chou TM, Hutchison SJ, Chatterjee K. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Circulation 1996; 93:1734.</a></li><li><a class="nounderline abstract_t">Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92:950.</a></li><li><a class="nounderline abstract_t">Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982; 65:40.</a></li><li><a class="nounderline abstract_t">Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258.</a></li><li><a class="nounderline abstract_t">Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35:60.</a></li><li><a class="nounderline abstract_t">Perondi R, Saino A, Tio RA, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85:2004.</a></li><li><a class="nounderline abstract_t">Kiowski W, Zuber M, Elsasser S, et al. Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure. Am Heart J 1991; 122:1382.</a></li><li><a class="nounderline abstract_t">Schneider CA, Voth E, Moka D, et al. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999; 34:1005.</a></li><li><a class="nounderline abstract_t">van den Heuvel AF, Dunselman PH, Kingma T, et al. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 2001; 37:470.</a></li><li><a class="nounderline abstract_t">Longobardi G, Ferrara N, Leosco D, et al. Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia. Am J Cardiol 1995; 76:255.</a></li><li><a class="nounderline abstract_t">Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50:367.</a></li><li><a class="nounderline abstract_t">Tomás JP, Moya JL, Barrios V, et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24:2109.</a></li><li><a class="nounderline abstract_t">Higuchi T, Abletshauser C, Nekolla SG, et al. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007; 14:805.</a></li><li><a class="nounderline abstract_t">Thorne S, Mullen MJ, Clarkson P, et al. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998; 32:110.</a></li><li><a class="nounderline abstract_t">Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94:130.</a></li><li><a class="nounderline abstract_t">Ceremuzyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80:331.</a></li><li><a class="nounderline abstract_t">Indolfi C, Piscione F, Russolillo E, et al. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am J Cardiol 1991; 68:1274.</a></li><li><a class="nounderline abstract_t">Sketch MH, Mooss AN, Butler ML, et al. Digoxin-induced positive exercise tests: their clinical and prognostic significance. Am J Cardiol 1981; 48:655.</a></li><li><a class="nounderline abstract_t">LeWinter MM, Crawford MH, O'Rourke RA, Karliner JS. The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram. Am Heart J 1977; 93:202.</a></li><li><a class="nounderline abstract_t">Clark PI, Glasser SP, Lyman GH, et al. Relation of results of exercise stress tests in young women to phases of the menstrual cycle. Am J Cardiol 1988; 61:197.</a></li><li><a class="nounderline abstract_t">Jaffe MD. Effect of oestrogens on postexercise electrocardiogram. Br Heart J 1976; 38:1299.</a></li><li><a class="nounderline abstract_t">Marmor A, Zeira M, Zohar S. Effects of bilateral hystero-salpingo-oophorectomy on exercise-induced ST-segment abnormalities in young women. Am J Cardiol 1993; 71:1118.</a></li><li><a class="nounderline abstract_t">Henzlova MJ, Croft LB, Diamond JA. Effect of hormone replacement therapy on the electrocardiographic response to exercise. J Nucl Cardiol 2002; 9:385.</a></li><li><a class="nounderline abstract_t">Bird JG, McCully RB, Pellikka PA, Kane GC. Dobutamine Stress Echocardiography: Impact of Abnormal Blood Potassium Levels on Cardiac Arrhythmias. J Am Soc Echocardiogr 2017; 30:595.</a></li><li><a class="nounderline abstract_t">Modesto KM, Møller JE, Freeman WK, et al. Safety of exercise stress testing in patients with abnormal concentrations of serum potassium. Am J Cardiol 2006; 97:1247.</a></li></ol></div><div id="topicVersionRevision">Topic 5305 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914678" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24737255" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750699" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206744" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672159" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The effects of medications on myocardial perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392846" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317905" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133636" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6883656" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2656267" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dipyridamole-echocardiography test: historical background and physiologic basis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14563595" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6282497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Regulation of large coronary arteries by beta-adrenergic mechanisms in the conscious dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564323" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of regional alpha- and beta-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723342" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Beta-adrenoceptor subtypes in human coronary artery: desensitization of beta 2-adrenergic vasorelaxation by chronic beta 1-adrenergic stimulation in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492555" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : S-C hemoglobin: a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1975525" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of the sympathetic nervous system in the pathogenesis of chronic stable angina. Implications for the mechanism of action of beta-blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8421980" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1681723" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of beta-blockade on the interpretation of the exercise ECG: ST level versus delta ST/HR index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565682" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2887403" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Beta blockers and the sensitivity of the thallium treadmill test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23351617" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264417" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569248" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effects of early administration of atropine during dobutamine stress echocardiography: advantages and disadvantages of early dobutamine-atropine protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772738" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962578" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of beta-blockade and atropine on ischemic responses in left ventricular regions subtending coronary stenosis during dobutamine stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683702" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The role of calcium antagonists in the treatment of myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3293393" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of nicardipine on coronary blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3891302" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diltiazem. A review of its pharmacological properties and therapeutic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/115306" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nifedipine therapy for stable angina pectoris: preliminary results of effects on angina frequency and treadmill exercise response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7317899" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The dose-response effects of nifedipine of ST-segment changes in exercise testing: preliminary studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184649" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043840" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of antianginal therapy with a calcium antagonist and nitrates on dobutamine-atropine stress echocardiography. Comparison with exercise electrocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626832" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626832" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6403258" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of effects of nifedipine and nitroglycerin on large and small coronary arteries and cardiac function in conscious dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/810610" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effects of diltiazem (CRD-401) on developed coronary collaterals in the dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867177" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492909" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Abnormal coronary vasomotion during exercise in patients with normal coronary arteries and reduced coronary flow reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Effects of Isosorbide Dinitrate on the Exercise Test</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006274" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953362" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Alterations in myocardial perfusion during exercise after isosorbide dinitrate infusion in patients with coronary disease: assessment by thallium-201 scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641379" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6273010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759064" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636260" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591820" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683143" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520782" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216965" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7618619" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049303" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Telmisartan improves endothelial function in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957573" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of candesartan on coronary flow reserve in patients with systemic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17907015" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669257" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674170" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264427" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659170" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7282547" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Digoxin-induced positive exercise tests: their clinical and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/319642" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337011" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relation of results of exercise stress tests in young women to phases of the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/188435" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of oestrogens on postexercise electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475882" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of bilateral hystero-salpingo-oophorectomy on exercise-induced ST-segment abnormalities in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161713" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of hormone replacement therapy on the electrocardiographic response to exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395912" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dobutamine Stress Echocardiography: Impact of Abnormal Blood Potassium Levels on Cardiac Arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616035" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety of exercise stress testing in patients with abnormal concentrations of serum potassium.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
